New drug cocktail targets Hard-to-Treat ovarian and endometrial cancers
NCT ID NCT03586661
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes that help cancer cells grow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- niraparib and copanlisib
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for people with recurrent gynecologic cancers that have stopped responding to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 31 participants, focused on finding the right dose and checking safety. It is not designed to prove the drugs work, and side effects may be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DELETERIOUS BRCA MUTANT RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- Immune-Boosting drug combo takes on Hard-to-Treat ovarian cancer
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Immune cells retrained to hunt ovarian cancer in new trial